Martin, MLoibl, SHyslop, TDe la Haba-Rodriguez, JAktas, BCirrincione, C TMehta, KBarry, W TMorales, SCarey, L AGarcia-Saenz, J APartridge, AMartinez-Jañez, NHahn, OWiner, EGuerrero-Zotano, AHudis, CCasas, MRodriguez-Martin, CFurlanetto, JCarrasco, EDickler, M N2023-01-252023-01-252019-06-02Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 Aug;117:91-98http://hdl.handle.net/10668/14217Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p  The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Advanced breast cancerBevacizumabEndocrine therapyPooled-analysisAdultAgedAged, 80 and overAntineoplastic combined chemotherapy protocolsBevacizumabBone neoplasmsBreast neoplasmsEvaluation studies as topicFemaleFollow-up studiesFulvestrantHumansLetrozoleMiddle agedNeoplasm recurrence, localPrognosisReceptors, estrogenReceptors, progesteroneSoft tissue neoplasmsSurvival rateTamoxifenresearch article31276981open accessNeoplasias de la mamaNeoplasias de los tejidos blandosNeoplasias óseasPronósticoProtocolos de quimioterapia combinada antineoplásicaReceptores de estrógenosReceptores de progesteronaRecurrencia local de neoplasia10.1016/j.ejca.2019.06.0021879-0852PMC6718694http://www.ejcancer.com/article/S0959804919303600/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718694/pdf